玻璃体内注射英夫利西单抗治疗白塞病难治性葡萄膜炎的安全性与疗效临床研究
本研究纳入20例白塞病难治性后葡萄膜炎患者,评估玻璃体内注射英夫利西单抗(1 mg/0.05 mL)的安全性及疗效。随访至18周,最佳矫正视力、黄斑中心凹厚度、玻璃体混浊及血管炎、视网膜炎、视乳头炎均较基线显著改善,未观察到显著电生理改变或眼部不良炎症反应。
要点
- 玻璃体内注射英夫利西单抗后,平均logMAR最佳矫正视力由基线0.94(20/160)改善至第18周0.36(20/40)(P < 0.0001)。
- 黄斑中心凹厚度由基线361 μm降至随访结束时180 μm(P < 0.0001),平均玻璃体混浊分级由2降至0.2(P < 0.05)。
- 研究期间未观察到显著电生理改变或眼部不良炎症反应。
核心结论
- 玻璃体内注射英夫利西单抗似乎对治疗白塞病葡萄膜炎安全有效,应被视为全身治疗的替代选择。
研究设计与样本
- 本研究为临床研究,纳入20例白塞病难治性后葡萄膜炎患者,玻璃体内注射英夫利西单抗1 mg/0.05 mL。
- 在基线、第1天及第2、4、6、8、12、18周评估最佳矫正视力、玻璃体混浊(0-4级)、血管炎、视网膜炎和视乳头病变。
- 在基线及第4、12、18周行光学相干断层扫描黄斑中心凹厚度、荧光素眼底血管造影和闪光视网膜电图检查。
主要发现
- 平均基线logMAR最佳矫正视力为0.94(20/160),第2周显著改善至0.6(20/80)(P < 0.0001),至第18周经三次注射达到0.36(20/40)(P < 0.0001)。
- 光学相干断层扫描平均黄斑中心凹厚度由基线361 μm显著降至随访结束时180 μm(P < 0.0001)。
- 平均玻璃体混浊分级由基线2显著降至随访结束时0.2(P < 0.05)。
- 血管炎患者数由基线15例显著减少至第18周1例,视网膜炎由基线9例减少至第4周0例,视乳头炎由基线2例减少至第4周0例(P < 0.05)。
- 研究期间未观察到显著电生理改变或眼部不良炎症反应。
关键数值与推荐
- 玻璃体内注射英夫利西单抗剂量为1 mg/0.05 mL。
- 玻璃体混浊按0-4级分级评估。
- 第18周时经三次注射平均logMAR最佳矫正视力达0.36(20/40)(P < 0.0001)。
临床怎么用
- 作者认为玻璃体内注射英夫利西单抗似乎对白塞病葡萄膜炎安全有效,应被视为全身治疗的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the safety and efficacy of intravitreal infliximab (1 mg/0.05 mL) in patients with refractory posterior uveitis in Behcet's disease. METHODS: Twenty patients were included in this study. Best corrected visual acuity (BCVA), vitreous haze (graded 0-4), vasculitis, retinitis, and papillopathy (presence or absence) were assessed at baseline, Day 1 and Week 2, 4, 6, 8, 12, and 18. Optical coherence tomography (OCT) central foveal thickness, fluorescein angiography, and flash electroretinogram were done at baseline and 4, 12, and 18 weeks. RESULTS: Mean baseline logMAR BCVA was 0.94 (20/160), had improved significantly by Week 2 to 0.6 (20/80) (P < 0.0001), and reached 0.36 (20/40) by Weeks 18 with three injections (P < 0.0001). Mean central foveal thickness OCT decreased significantly from baseline 361 μm to 180 μm at the end of follow-up (P < 0.0001). Profound decrease in mean vitreous haze gradings from two to 0.2 by the end follow-up (P < 0.05). There was a significant reduction in the number of patients with vasculitis (15 at baseline to 1 weeks at 18 weeks), retinitis (nine at baseline to none at 4 weeks), and papillitis (two at baseline to none at 4 weeks) (P < 0.05). No significant electrophysiological changes or ocular adverse inflammatory reactions were observed during the study period. CONCLUSION: Intravitreal infliximab appeared to be safe and effective in treating uveitis in Behcet's disease and should be considered as an alternative to systemic therapies.
引用
- Hamza MM, Macky TA, Sidky MK, et al. INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study. Retina. 2016. PMID: 27870802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。